Publications
1 A randomised trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected subjects. The MaxCmin2 trial. UB Dragsted, J Gerstoft, M Youle, Z Fox, M Losso, J Benetucci, DT Jayawwera, A Rieger, JN Bruun, A Castagna, B Gazzard, S Walmsley, A Hill, and JD Lundgren for the MaxCmin2 trial group.
Antivir Ther. 2005;10(6):735-43. abstract
Presentations
11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004
1 Lipid Profiles of Patients Enrolled in the MaxCmin2 Trial: A Randomised, Open-label Multi-centre Comparative Trial Evaluating the Safety and Efficacy of Lopinavir/ Ritonavir (400/100 mg twice daily) vs Saquinavir/Ritonavir SQV/r (1000/100 mg twice daily). S L Walmsley, J Benetucci, A Brutus, N Clumeck, U B Dragsted, B Gazzard, N Obel, P Vernazza, Z Fox, J D Lundgren and on behalf of the MaxCmin2 Trial Group.
(MaxCmin2 720)
Updated: 05 Oct 2010